[go: up one dir, main page]

WO2005119260A3 - Methods for predicting and monitoring response to cancer therapy - Google Patents

Methods for predicting and monitoring response to cancer therapy Download PDF

Info

Publication number
WO2005119260A3
WO2005119260A3 PCT/EP2005/005787 EP2005005787W WO2005119260A3 WO 2005119260 A3 WO2005119260 A3 WO 2005119260A3 EP 2005005787 W EP2005005787 W EP 2005005787W WO 2005119260 A3 WO2005119260 A3 WO 2005119260A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
predicting
cancer therapy
monitoring response
differentially expressed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/005787
Other languages
French (fr)
Other versions
WO2005119260A2 (en
Inventor
Marc Munnes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Priority to EP05745597A priority Critical patent/EP1756309A2/en
Priority to JP2007513829A priority patent/JP2008502326A/en
Priority to CA002568732A priority patent/CA2568732A1/en
Publication of WO2005119260A2 publication Critical patent/WO2005119260A2/en
Publication of WO2005119260A3 publication Critical patent/WO2005119260A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G01N33/575—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention provides novel compositions, methods and uses, for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia and breast cancer. The invention further relates to genes that are differentially expressed in breast tissue of breast cancer patients versus those of normal 'healthy' tissue. Differentially expressed genes for the identification of patients which are likely to respond to chemotherapy are also provided.
PCT/EP2005/005787 2004-06-03 2005-05-30 Methods for predicting and monitoring response to cancer therapy Ceased WO2005119260A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP05745597A EP1756309A2 (en) 2004-06-03 2005-05-30 Methods for predicting and monitoring response to cancer therapy
JP2007513829A JP2008502326A (en) 2004-06-03 2005-05-30 Methods for predicting and monitoring response to cancer treatment
CA002568732A CA2568732A1 (en) 2004-06-03 2005-05-30 Methods for predicting and monitoring response to cancer therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04013107 2004-06-03
EP04013107.0 2004-06-03

Publications (2)

Publication Number Publication Date
WO2005119260A2 WO2005119260A2 (en) 2005-12-15
WO2005119260A3 true WO2005119260A3 (en) 2006-11-09

Family

ID=35463523

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/005787 Ceased WO2005119260A2 (en) 2004-06-03 2005-05-30 Methods for predicting and monitoring response to cancer therapy

Country Status (4)

Country Link
EP (1) EP1756309A2 (en)
JP (1) JP2008502326A (en)
CA (1) CA2568732A1 (en)
WO (1) WO2005119260A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2380978A3 (en) * 2006-02-03 2012-02-29 MessengerScape Co. Ltd. Gene group applicable to cancer prognostication
EP1996206A4 (en) * 2006-03-02 2010-09-22 Agency Science Tech & Res SENSITIZING A CELL TO ANTICANCER TREATMENT BY MODULATING THE ACTIVITY OF A NUCLEIC ACID ENCODING THE RPS27L PROTEIN
WO2008062105A1 (en) * 2006-11-24 2008-05-29 Licentia Ltd. Method for predicting the response to a therapy
WO2009032084A1 (en) * 2007-08-28 2009-03-12 Merck & Co., Inc. Expression profiles of biomarker genes in notch mediated cancers
WO2009090287A1 (en) * 2008-01-17 2009-07-23 Fundació Institut de Recerca de L'Hospital Universitari Vall d'Hebron Cirp-based antitumour compounds
WO2010002356A1 (en) * 2008-07-03 2010-01-07 National University Hospital Methods for predicting tumor response to chemotherapy and selection of tumor treatment
CA2760333A1 (en) 2009-05-01 2010-11-04 Genomic Health Inc. Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy
US20130190251A1 (en) * 2010-03-18 2013-07-25 Veronique Witko-Sarsat Method for predicting the responsiveness to chemotherapy
DK2913405T3 (en) 2010-07-27 2017-02-13 Genomic Health Inc PROCEDURE FOR USING GENEPRESSION FOR DETERMINING THE PROSTATE CANCER FORECAST
JP6483681B2 (en) * 2013-07-29 2019-03-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Real-time feedback system control technology platform that dynamically changes stimuli
EP3258923A4 (en) * 2015-02-19 2019-01-16 Mayo Foundation For Medical Education And Research METHODS AND SUBSTANCES FOR EVALUATING RESPONSE TO CHEMOTHERAPY AND TREATING CANCER
WO2018225062A1 (en) * 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer therapy and kit therefor
US12016900B2 (en) 2017-06-04 2024-06-25 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
US12070489B2 (en) 2018-12-12 2024-08-27 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with a cancer therapy in combination with another therapeutic agent
US20250118405A1 (en) 2021-08-11 2025-04-10 OncoHost Ltd. Predicting patient response

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092854A2 (en) * 2001-05-16 2002-11-21 Novartis Ag Genes expressed in breast cancer as prognostic and therapeutic targets
EP1365034A2 (en) * 2002-05-21 2003-11-26 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
US20040058340A1 (en) * 2001-06-18 2004-03-25 Hongyue Dai Diagnosis and prognosis of breast cancer patients

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092854A2 (en) * 2001-05-16 2002-11-21 Novartis Ag Genes expressed in breast cancer as prognostic and therapeutic targets
US20040058340A1 (en) * 2001-06-18 2004-03-25 Hongyue Dai Diagnosis and prognosis of breast cancer patients
EP1365034A2 (en) * 2002-05-21 2003-11-26 Bayer Aktiengesellschaft Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK 4 February 2003 (2003-02-04), OMASA ET AL.: "Homo sapiens FXYD domain-containing ion transport regulator 5", XP002364519, retrieved from NCBI Database accession no. NM_014164 *
DRESSMAN M A ET AL: "Gene expression profiling detects gene amplification and differentiates tumor types in breast cancer", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 63, no. 9, 1 May 2003 (2003-05-01), pages 2194 - 2199, XP002317347, ISSN: 0008-5472 *
MODLICH OLGA ET AL: "Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. 1 OCT 2004, vol. 10, no. 19, 1 October 2004 (2004-10-01), pages 6418 - 6431, XP009060572, ISSN: 1078-0432 *

Also Published As

Publication number Publication date
EP1756309A2 (en) 2007-02-28
JP2008502326A (en) 2008-01-31
CA2568732A1 (en) 2005-12-15
WO2005119260A2 (en) 2005-12-15

Similar Documents

Publication Publication Date Title
EP1522594A3 (en) Methods and kits for investigating cancer
WO2007006408A3 (en) Methods and kits for predicting and monitoring direct response to cancer therapy
WO2005047534A3 (en) Methods and compositions for the response prediction of malig-nant neoplasia to treatment
WO2007015947A3 (en) Methods and kits for the prediction of therapeutic success, recurrence free and overall survival in cancer therapies
EP1365034A3 (en) Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
WO2005119260A3 (en) Methods for predicting and monitoring response to cancer therapy
PH12015501744B1 (en) Therapeutic and diagnostic target for cancer comprising dll3 binding reagents
WO2004065583A3 (en) Gene expression markers for breast cancer prognosis
WO2004070062A3 (en) Compositions and methods for diagnosing and treating cancers
WO2003042661A3 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
WO2004008147A3 (en) Diagnosis and prevention of cancer cell invasion
WO2009013538A3 (en) Glycosylation markers for cancer and chronic inflammation
WO2007109236A3 (en) Microrna fingerprints during human megakaryocytopoiesis
WO2004061423A3 (en) Compositions and methods for diagnosing and treating colon cancers
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2008008430A3 (en) Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
EP2258873A3 (en) Gene expression profiling in biopsied tumor tissues
WO2003065006A3 (en) Methods and compositions for treating cancer
WO2003087831A3 (en) Proteins involved in breast cancer
WO2005001092A3 (en) Compositions and methods for diagnosing and treating cancers
WO2005001046A3 (en) Methods for predicting the course of a malignant disease
AU2002338852A1 (en) Genes and proteins for prevention, prediction, prognosis and therapy of cardiovascular disease
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2006061216A3 (en) Genetic alteration useful for the response prediction of malignant neoplasia to taxane-based medical treatment

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005745597

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2568732

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007513829

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 2005745597

Country of ref document: EP